Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.

J Clin Oncol · 2023 · PMC10602497 · PMID 37364223

Europe PMC DOI

hedged sentence

0.0250

closest p · 0.5× alpha

0.0250

boldest claim

The sentences

did not reach statistical significanceP < .025actually significant

On the basis of protocol-prespecified Hochberg step-up multiplicity adjustment, the primary end point did not reach statistical significance ( P < .025).

also in 17,681 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.